Several companies have seen triple-digit gains in the first four months of 2026, often led by specialized healthcare breakthroughs or critical AI hardware components.
: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy. best buy stocks
: Up roughly 394% YTD following the commercial launch of its cancer therapy, Anktiva, in Saudi Arabia and expansion into Europe. Several companies have seen triple-digit gains in the
: Up 301% YTD as of April 2026. It is currently the top performer in the S&P 500, benefiting from soaring demand for NAND flash memory used in AI data centers. best buy stocks
: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.